MicroRNA-29b Inhibits Diabetic Nephropathy in db/db Mice

Chen, Haiyong; Zhong, Xiang; Huang, Xiao Ru; Meng, Xiao‐Ming; You, Yong‐Ke; Chung, Arthur C.K.; Lan, Hui‐Yao

doi:10.1038/mt.2013.235

Cited by 166 publications

(168 citation statements)

References 61 publications

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…More severe renal phenotypes were detected in miR-21 knockout mice crossed with TGF-␤1 transgenic mice relative to TGF-␤1 transgenic mice (77). Interestingly some miRNAs like the miR-29 family members can directly regulate ECM accumulation because these miRNAs target multiple collagens and hence a decrease in their levels can augment collagen deposition in the kidney or in renal cells treated with TGF-␤1 or HG (22,34,73,148). Importantly, miR-29b overexpression was found to significantly alleviate DN in db/db mice (22).…”

Section: Diabetic Nephropathymentioning

confidence: 99%

“…Interestingly some miRNAs like the miR-29 family members can directly regulate ECM accumulation because these miRNAs target multiple collagens and hence a decrease in their levels can augment collagen deposition in the kidney or in renal cells treated with TGF-␤1 or HG (22,34,73,148). Importantly, miR-29b overexpression was found to significantly alleviate DN in db/db mice (22). Interestingly, an antidiabetic drug, linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was shown to upregulated miR-29 and prevent fibrosis in a mouse model of DN (59).…”

Section: Diabetic Nephropathymentioning

confidence: 99%

See 1 more Smart Citation

Mini-review: emerging roles of microRNAs in the pathophysiology of renal diseases

Bhatt

Kato

Natarajan

2016

American Journal of Physiology-Renal Physiology

View full text Add to dashboard Cite

MicroRNAs (miRNA) are endogenously produced short noncoding regulatory RNAs that can repress gene expression by posttranscriptional mechanisms. They can therefore influence both normal and pathological conditions in diverse biological systems. Several miRNAs have been detected in kidneys, where they have been found to be crucial for renal development and normal physiological functions as well as significant contributors to the pathogenesis of renal disorders such as diabetic nephropathy, acute kidney injury, lupus nephritis, polycystic kidney disease, and others, due to their effects on key genes involved in these disease processes. miRNAs have also emerged as novel biomarkers in these renal disorders. Due to increasing evidence of their actions in various kidney segments, in this mini-review we discuss the functional significance of altered miRNA expression during the development of renal pathologies and highlight emerging miRNA-based therapeutics and diagnostic strategies for early detection and treatment of kidney diseases.

show abstract

Section: Diabetic Nephropathymentioning

confidence: 99%

Section: Diabetic Nephropathymentioning

confidence: 99%

Mini-review: emerging roles of microRNAs in the pathophysiology of renal diseases

Bhatt

Kato

Natarajan

2016

American Journal of Physiology-Renal Physiology

View full text Add to dashboard Cite

show abstract

“…Индуцируемые TGF-β1 механизмы фиброгенеза модулируют также представители семейства miR-29 (miR-29a, miR-29b, miR-29c), оказывая непосред-ственное влияние на гены, кодирующие белки ЭЦМ, в том числе коллагены I и IV [34,35]. Показано, что утрата miR-29b ускоряет, а избыток -предупреждает опосре-дованные TGF-β1 процессы формирования почечного фиброза [34].…”

Section: сахарный диабет Diabetes Mellitusunclassified

New insights on microRNAs in diabetic nephropathy: potential biomarkers for diagnosis and therapeutic targets

Сергеевна²,

Bobkova

et al. 2017

Diabetes mellitus

View full text Add to dashboard Cite

Вопросы патогенезаPathogenesis ахарный диабет (СД) -одна из серьезных ме-дико-социальных и экономических проблем современного здравоохранения. Наиболее опасные последствия глобальной эпидемии СД связаны с его сосудистыми осложнениями, в частности с диа-бетической нефропатией (ДН), которая является при-чиной хронической почечной недостаточности (ХПН), высокого сердечно-сосудистого риска, инвалидизации и смертности больных [1]. В этой связи раннее выявле-ние больных СД, предрасположенных к развитию ДН, может служить важным шагом к более эффективным профилактическим и лечебным мероприятиям с целью предотвращения наступления неблагоприятных исходов.Единственным используемым до настоящего вре-мени в рутинной практике методом ранней диагностики ДН является определение микроальбуминурии (МАУ). В современных экспериментальных и клинических ис-следованиях доказана взаимосвязь между альбумину-рией и выраженностью морфологических изменений в почках, однако начальные структурные признаки ДН появляются при еще нормальной экскреции альбумина с мочой, а повышение экскреции альбумина выше нормы

show abstract

“…injection of LNA antisense oligonucleotides improved glucose homeostasis in mice with diet-induced obesity (Zhou et al 2012). Recently, nonviral-based miRNA regulation has been successfully developed to treat diabetic complications and other diseases, such as diabetic nephropathy, lung fibrosis, and cardiac fibrosis (Xiao et al 2012, Chen et al 2014, Zhang et al 2014. These studies showed that miRNA regulation by virus-based and reagent-based transfection may be applicable to T1D and T2D though the potential risks of the therapy need to be further investigated.…”

Section: Pkb (Akt) Signaling (Insulin Sensitivity)mentioning

confidence: 99%

Application of microRNAs in diabetes mellitus

Chen¹,

Lan²,

Roukos³

et al. 2014

Journal of Endocrinology

105

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small molecules negatively regulating gene expression by diminishing their target mRNAs. Emerging studies have shown that miRNAs play diverse roles in diabetes mellitus. Type 1 diabetes (T1D) and T2D are two major types of diabetes. T1D is characterized by a reduction in insulin release from the pancreatic b-cells, while T2D is caused by islet b-cell dysfunction in response to insulin resistance. This review describes the miRNAs that control insulin release and production by regulating cellular membrane electrical excitability (ATP:ADP ratio), insulin granule exocytosis, insulin synthesis in b-cells, and b-cell fate and islet mass formation. This review also examines miRNAs involved the insulin resistance of liver, fat, and skeletal muscle, which change insulin sensitivity pathways (insulin receptors, glucose transporter type 4, and protein kinase B pathways). This review discusses the potential application of miRNAs in diabetes, including the use of gene therapy and therapeutic compounds to recover miRNA function in diabetes, as well as the role of miRNAs as potential biomarkers for T1D and T2D.

show abstract

MicroRNA-29b Inhibits Diabetic Nephropathy in db/db Mice

Cited by 166 publications

References 61 publications

Mini-review: emerging roles of microRNAs in the pathophysiology of renal diseases

Mini-review: emerging roles of microRNAs in the pathophysiology of renal diseases

New insights on microRNAs in diabetic nephropathy: potential biomarkers for diagnosis and therapeutic targets

Application of microRNAs in diabetes mellitus

Contact Info

Product

Resources

About